Rubicon Research

Rubicon Research is engaged in the business of developing, licensing acquiring, distributing, repacking, buying, selling, trading (whether domestically or outside), manufacturing or getting manufactured pharmaceutical products (prescribed and over the counter), whether patented and non-patented, fast moving consumer goods, consumer healthcare and prophylactic, wellness and hygiene, healthcare technology and data analytics and buying, selling, acquiring, building a brand of product categories as authorized under its memorandum of association. Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from `Rubicon Research Private Limited' to `Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra. The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern. In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025. The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025.